Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Seasonal Influenza Vaccine Supply for the U.S. 2014-2015 Influenza Season

How much influenza vaccine is projected to be available for the 2014-15 influenza season?

As of mid-October, seven influenza vaccine manufacturers are projecting that as many as 151 million to 156 million doses of influenza vaccine will be available for use in the United States during the 2014-2015 influenza season.

How much thimerosal-free influenza vaccine is expected to be available for the 2014-15 season?

For the 2014-15 season, manufacturers will produce approximately 105 million doses of thimerosal-free or preservative-free (trace thimerosal) influenza vaccine.

Can I still buy influenza vaccine for the 2014-15 season?

Influenza vaccine pre-booking typically occurs between January and March, though most preparations of vaccine should still be available for purchase. Providers should contact distributors and local vendors about remaining supply. Information about manufacturers and distributors who still have influenza vaccine available for sale can be found at http://www.preventinfluenza.org/ivats/

What can we anticipate in terms of the timing of vaccine availability for the 2014-15 season?

Distribution of products began in August and manufacturer projections indicate that the majority of vaccine will be distributed by the end of October. However, some vaccine distribution will likely continue into November.

Are all influenza vaccines the same?

Different influenza vaccine preparations have different indications as licensed by the FDA. See the table below for an overview of these indications.

 Top of Page

TABLE 1. Influenza Vaccines — United States, 2014–15 Influenza Season*

Vaccine

Trade name

Manufacturer

Presentation

Mercury content from thimerosal
(µg Hg/0.5 mL)

Ovalbulmin content
(μg/0.5 mL)

Age indications

Route

Inactivated Influenza Vaccine, Quadrivalent (IIV4), Standard Dose

Fluarix® Quadrivalent

GlaxoSmithKline

0.5 mL single-dose prefilled syringe

≤0.05

≥3 yrs.

IM

FluLaval® Quadrivalent

ID Biomedical Corporation of Quebec (distributed by GlaxoSmithKline)

0.5 mL single-dose prefilled syringe

≤0.3

≥3 yrs

IM

5.0 mL multidose vial

<25

≤0.3

≥3 yrs

IM

Fluzone® Quadrivalent

Sanofi Pasteur

0.25 mL single-dose prefilled syringe

****

6-35 mos.

IM

0.5 mL single-dose prefilled syringe

****

≥36 mos.

IM

0.5 mL single-dose vial

****

≥36 mos.

IM

5.0 mL multidose vial

25

****

≥6 mos.

IM

Inactivated Influenza Vaccine, Trivalent (IIV3), Standard Dose

Afluria®

bioCSL

0.5 mL single-dose prefilled syringe

<1

≥9 yrs.†††

IM

5.0 mL multidose vial

24.5

<1

≥9 yrs.†††

IM

Fluarix®

GlaxoSmithKline

0.5 mL single-dose prefilled syringe

≤0.05

≥3 yrs.

IM

FluLaval®

ID Biomedical Corporation of Quebec (distributed by GlaxoSmithKline)

0.5 mL single-dose prefilled syringe

≤0.3

≥3 yrs

IM

5.0 mL multidose vial

≤25

≤0.3

≥3 yrs

IM

Fluvirin®

Novartis Vaccines and Diagnostics

0.5 mL single-dose prefilled syringe

≤1

≤1

≥4 yrs.

IM

5.0 mL multidose vial

25

≤1

≥4 yrs.

IM

Fluzone®

Sanofi Pasteur

0.5 mL single-dose prefilled syringe

****

≥36 mos.

IM

5.0 mL multidose vial

25

****

≥6 mos.

IM

Fluzone® Intradermal§

Sanofi Pasteur

0.1 mL prefilled microinjection system

****

18-64 yrs.

ID**

Inactivated Influenza Vaccine, Trivalent, Standard Dose, Cell Culture-based (ccllV3)

Flucelvax®

Novartis Vaccines and Diagnostics

0.5 mL single-dose prefilled syringe

†††

≥18 yrs.†††

IM

Inactivated Influenza Vaccine, Trivalent (IIV3), High Dose**

Fluzone® High-Dose††

Sanofi Pasteur

0.5 mL single-dose prefilled syringe

****

≥65 yrs.

IM

Recombinant Influenza Vaccine, Trivalent (RIV3)

FluBlok®

Protein Sciences

0.5 mL single-dose vial

0

≥18 yrs.

IM

Live-attenuated Influenza Vaccine, Quadrivalent (LAIV4)

FluMist® Quadrivalent§§

MedImmune

0.2 mL prefilled intranasal sprayer

≤0.24 (per 0.2 mL)

2-49 yrs.

IN

Abbreviations: IM = intramuscular; ID = intradermal; IN = intranasal; ACIP = Advisory Committee on Immunization Practices.

* Immunization providers should check Food and Drug Administration–approved prescribing information for 2014–15 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm093833.htm.

† For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Specific guidance regarding site and needle length for intramuscular administration can be found in ACIP's General Recommendations on Immunization (available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm).

§ Trivalent inactivated vaccine, intradermal: A 0.1-mL dose contains 9 µg of each vaccine antigen (27 µg total).

** The preferred site is over the deltoid muscle. Fluzone Intradermal is administered using the delivery system included with the vaccine.

†† Trivalent inactivated vaccine, high-dose: A 0.5-mL dose contains 60 µg of each vaccine antigen (180 µg total).

§§ FluMist is shipped refrigerated and stored in the refrigerator at 35°F–46°F (2°C–8°C) after arrival in the vaccination clinic. The dose is 0.2 mL divided equally between each nostril. Health care providers should consult the medical record, when available, to identify children aged 2 through 4 years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving LAIV, parents or caregivers of children aged 2 through 4 years should be asked, "In the past 12 months, has a health care provider ever told you that your child had wheezing or asthma?" Children whose parents or caregivers answer "yes" to this question and children who have asthma or who had a wheezing episode noted in the medical record within the past 12 months should not receive FluMist.

*** Age indication per package insert is ≥5 years; however, ACIP recommends Afluria not be used in children aged 6 months through 8 years because of increased risk for febrile reactions noted in this age group with bioCSL's 2010 Southern Hemisphere IIV3. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child aged 5 through 8 years who has a medical condition that increases the child's risk for influenza complications, Afluria can be used; however, providers should discuss with the parents or caregivers the benefits and risks of influenza vaccination with Afluria before administering this vaccine. Afluria may be used in persons aged ≥9 years.

††† Information not included in package insert. Estimated to contain <50 femtograms (5x10-8 µg) of total egg protein (of which ovalbumin is a fraction) per 0.5 mL dose of Flucelvax.

§§§ Available upon request from Sanofi Pasteur (telephone: 1-800-822-2463; e-mail: mis.emails@sanofipasteur.com).

Flu Clinic Locations Open To The Public

 Top of Page

Top